Genovefa Kolovou
Genovefa Kolovou is an expert in Cardiology at Metropolitan Hospital (Greece). As of September 2026, ScienceLeadR ranks Genovefa Kolovou in the top 1% of experts worldwide for Hypercholesterolemia, Hyperlipidemias and Dyslipidemias. Genovefa Kolovou has authored 390 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 2 of them ongoing. SLR score: 1,175 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Nutrition - Endocrinology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2002 - 2026
Number : 390
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prevalence, Clinical Characteristics, and Therapeutic Underachievement in Familial Hypercholesterolemia: Results from the GRegistry-FH Population-Based Study in Greece. PMID 42452587 — hyperlipoproteinemia type ii, phenotype, underachievement, prevalence, therapeutics, hypercholesterolemia | J Clin Med | 2026 | 0 |
| Hellenic Postprandial Lipemia Study (HPLS): A Prospective Cohort Trial on the Effect of Statins on Postprandial Hypertriglyceridemia. PMID 41588896 — dyslipidemias, hypertriglyceridemia, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, triglycerides | Curr Vasc Pharmacol | 2026 | 0 |
| Lomitapide response in a cohort of patients with homozygous familial hypercholesterolemia and the potential influence of MTTP gene variants. PMID 41088305 — hyperlipoproteinemia type ii, genes, cholesterol, ldl, rare diseases, lipoproteins, cholesterol, therapeutics, hypercholesterolemia, homozygous familial hypercholesterolemia | Orphanet J Rare Dis | 2025 | 0 |
| HDL cholesterol as an associate of prevalent coronary artery disease in heterozygous Familial hypercholesterolemia beyond LDL cholesterol. PMID 40974504 — hyperlipoproteinemia type ii, cholesterol, ldl, coronary artery disease, arteries, hormones, cholesterol, cholesterol, hdl, hypercholesterolemia | Endocrine | 2025 | 0 |
| Beyond lipid levels: unraveling the hypertensive factor in familial hypercholesterolemia. The HELLAS-FH registry. PMID 40691322 — registries, hyperlipoproteinemia type ii, hypertension, blood, stroke, blood pressure, arteries, cholesterol, prevalence, risk factors, hypercholesterolemia | J Hum Hypertens | 2025 | 0 |
Clinical Studies 10
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Long term safety and tolerability of inclisiran in participants with heterozygous familial hypercholesterolaemia or homozygous familial hypercholesterolaemia who have completed the adolescent ORION 16 or ORION 13 studies 2023-507278-41-00 — hyperlipoproteinemia type ii, safety, adolescent, hypercholesterolemia, homozygous familial hypercholesterolemia | Phase 3 | Active not recruiting | 2023 |
| Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia NCT06832371 — hyperlipoproteinemia type ii, cholesterol, ldl, cardiovascular diseases, dyslipidemias, lipid metabolism disorders, cholesterol, atherosclerosis, therapeutics, genetic diseases, inborn, hypercholesterolemia, homozygous familial hypercholesterolemia, lipids | N/A | Active not recruiting | 2024 |
LeadR Networks
Main global connection map